News

On March 9, members of the Duke Human Vaccine Institute (DHVI) gathered virtually for the annual DHVI Service & Core Values Awards Ceremony to celebrate 

A new Nature Medicine paper highlights how 40 years of HIV research reshaped far more than the fight against one virus. What began as an urgent global health response helped fuel breakthroughs that now power treatments for cancer, tuberculosis, hepatitis, and even COVID-19 — thanks to sustained U.S. investment and collaboration across universities, industry, and government.

DHVI member Georgia Tomaras, PhD, the A. Geller Distinguished Professor for Research in Immunology received a Research Mentoring Award, which recognizes excellence in mentoring across clinical, translational, population health, and basic sciences. She was honored for career mentoring in basic science.

Duke Human Vaccine Institute (DHVI) director Barton F.

Duke University School of Medicine has joined the Global Virus Network (GVN) as one of its newest Centers of Excellence. Collaborating entities include the Duke Research and Discovery @RTP, the Duke Global Health Institute and the Duke Human Vaccine Institute (DHVI).

Highly specific HIV antibodies could be induced by vaccination using a new strategy developed by researchers at the Duke Human Vaccine Institute

The Duke Human Vaccine Institute has been awarded a $7 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), to manufacture H5N1 avian flu vaccines for use in cli

A Duke University School of Medicine study in Molecular Cell provides the most detailed look yet at the SARS-CoV-2

The Duke Human Vaccine Institute received funding from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health, to manufacture H5N1 avian fl

Barton F. Haynes, MD, HS’73 -’75, is the Frederic M.